|
Persistent HPV Infection in Women at Risk for Cervix Cancer
|
5U01CA078527-20
|
$581,591
|
|
BURK, ROBERT
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
(7) Novel imaging devices for measurement and control of tumor microenvironments
|
1R01CA216248-01
|
$565,675
|
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
5R01CA178394-04
|
$346,525
|
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Proton-coupled folate/antifolate transport
|
5R01CA082621-20
|
$483,169
|
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Nemours NCI Community Oncology Research Program (NCORP)
|
5UG1CA189958-04
|
$388,215
|
|
SANDLER, ERIC
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
Exploiting the immune response to detect pathogen-induced cancers
|
5R01CA199948-03
|
$436,974
|
|
LABAER, JOSHUA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Charge sensitive optical detection for high-throughput study of small molecules
|
5R33CA202834-02
|
$389,677
|
|
TAO, NONGJIAN
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Colon Cancer Chemoprevention with Phosphodiesterase-5 Inhibitors
|
5R01CA172627-05
|
$311,250
|
$311,250
|
BROWNING, DARREN
|
AUGUSTA UNIVERSITY
|
|
TREM-1 and Its Implications to Cancer
|
5R01CA172230-04
|
$315,400
|
|
HORUZSKO, ANATOLIJ
|
AUGUSTA UNIVERSITY
|
|
Role of SLC13A3 in Renal Cell Carcinoma
|
5F31CA210612-02
|
$33,744
|
|
JORDAN, ANDRE
|
AUGUSTA UNIVERSITY
|
|
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma
|
5R01CA176691-04
|
|
$0
|
LOKESHWAR, VINATA
|
AUGUSTA UNIVERSITY
|
|
Role of heat shock transcription factor HSF1 in tumoroginesis
|
5R01CA062130-22
|
$556,510
|
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
|
Bay Area Tumor Institute NCORP
|
5UG1CA189817-04
|
$690,000
|
|
BAILEY, LISA
|
BAY AREA TUMOR INSTITUTE
|
|
High Resolution Microendoscopy for the Management of Esophageal Neoplasia
|
5R01CA181275-04
|
$1,088,646
|
|
ANANDASABAPATHY, SHARMILA
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ3) Identifying Novel Pharmacologic Risk factors for Common Non-AIDS Defining Cancers in Individuals with Well-controlled HIV Infection
|
5R01CA206476-02
|
$772,521
|
$772,521
|
CHIAO, ELIZABETH
|
BAYLOR COLLEGE OF MEDICINE
|
|
ALK causes TGF-beta insensitivity in lung cancer cells
|
5R21CA209007-02
|
$206,843
|
|
FENG, XIN-HUA
|
BAYLOR COLLEGE OF MEDICINE
|
|
MECHANISMS OF AR-ER COLLABORATION IN HORMONE RESISTANCE AND METASTASIS OF BREAST CANCER
|
1R01CA207270-01A1
|
$362,569
|
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Integration of Predictive Biomarkers of Hormone Resistance in Breast Cancer
|
5R01CA072038-19
|
$320,963
|
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Epigenomic reprogramming driven by mutant ER? in metastatic breast cancer
|
5F31CA210385-02
|
$43,993
|
|
GATES, LEAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mechanisms of KLF4 suppression in pediatric leukemia
|
1R01CA207086-01A1
|
$326,540
|
|
LACORAZZA, DANIEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
Ruxolitinib for Preventing Breast Cancer in Women on Neuroleptics
|
1R01CA205594-01A1
|
$362,569
|
$362,569
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
In Vivo Drug Testing of Pediatric CNS Tumors Using Patient Derived Orthotopic Xenograft Models
|
5U01CA199288-03
|
$578,693
|
|
LI, XIONAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational control of EMT by the CELF1 RNA Binding Protein
|
5R01CA190467-03
|
$362,569
|
|
NEILSON, JOEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S1
|
$118,333
|
$4,733
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S2
|
$118,875
|
$4,755
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S3
|
$122,250
|
$4,890
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S4
|
$250,002
|
$10,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-11
|
$3,253,119
|
$130,125
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-04
|
$2,300,000
|
$138,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Gut L-Histidine Metabolism and Histamine Signaling in Colonic Neoplasia
|
5U01CA170930-05
|
$452,105
|
|
VERSALOVIC, JAMES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Drugging the Undruggable Coactivators using Small Molecule Inhibitors
|
1R01CA207701-01A1
|
$427,784
|
|
WANG, JIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Aspirin and Cancer Prevention in Lynch Syndrome: From Cell to Population Data
|
5U01CA187956-04
|
$496,015
|
$496,015
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
Reducing risk of Anthracycline-related heart failure after childhood cancer
|
5R01CA196854-03
|
$610,389
|
$610,389
|
ARMENIAN, SARO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumors
|
2R01CA155769-06A1
|
$410,877
|
|
BADIE, BEHNAM
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Optimizing Busulfan: Efficacy Toxicity and Pharmacometabolomics
|
5R01CA182963-05
|
$515,038
|
|
MCCUNE, JEANNINE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S1
|
$73,297
|
$2,199
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S2
|
$124,999
|
$3,750
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
5P30CA033572-34
|
$2,446,682
|
$73,400
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Combating Resistance to Antiangiogenic Therapy in Renal Cell Carcinoma
|
5R01CA196996-03
|
$398,025
|
|
BHATT, RUPAL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Basic and Translational studies of Ras-mutant colorectal cancer
|
5R01CA178017-04
|
$359,556
|
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A multi-faceted approach to identifying K-Ras synthetic lethal relationships
|
5U01CA199252-03
|
$1,041,188
|
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Cohesin Mutations in Acute Myelogenous Leukemia
|
1R01CA204231-01A1
|
$391,588
|
|
RAO, SRIDHAR
|
BLOODCENTER OF WISCONSIN, INC.
|
|
Discovery and targeting of apoptosis resistance mechanisms in high-risk T-ALL
|
5R01CA193651-03
|
$446,954
|
|
GUTIERREZ, ALEJANDRO
|
BOSTON CHILDREN'S HOSPITAL
|
|
Development of novel selective Rac inhibitors for refractory leukemias
|
5R01CA202756-02
|
$603,034
|
|
WILLIAMS, DAVID
|
BOSTON CHILDREN'S HOSPITAL
|
|
Molecular Mechanisms Regulating the Alternative Lengthening of Telomeres Pathway
|
5R01CA201446-02
|
$376,294
|
|
FLYNN, RACHEL
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
PAX3 pathways in melanoma
|
5R01CA184001-04
|
$376,389
|
|
LANG, DEBORAH
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
A Prospective Investigation of the Oral Microbiome and Pancreatic Cancer
|
5U01CA187508-03
|
$590,572
|
|
PALMER, JULIE
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Enzyme-instructed self-assembly for molecular anticancer nanomedicines
|
5R01CA142746-08
|
$368,145
|
|
XU, BING
|
BRANDEIS UNIVERSITY
|
|
The VITamin D and OmegA-3 TriaL (VITAL)
|
5R01CA138962-09
|
$3,203,095
|
$3,203,095
|
MANSON, JOANN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Understanding How Breast Cancers Activate and Respond to the Systemic Environment
|
5R01CA166284-06
|
$356,692
|
|
MCALLISTER, SANDRA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
Total relevant funding to Chemoprevention for this search: $98,736,199
|